Biogen Agreement Further Validates Anavex Life Sciences (AVXL) AV2-73 - FBR
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- Shares jump on tech boost; fragile yen on intervention watch
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Oil prices steady after rallying on US stock decline, business data
- Yen on the brink, but Tesla pulls back
- Dollar recovers from PMI slump, yen closes in on 155 per dollar
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla, AT&T, Biogen and Hasbro rise premarket; Uber, Enphase fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
Anavex Life Sciences (AVXL) Surges Higher; Stock Up 47%
September 28, 2016 10:12 AM EDTAnavex Life Sciences (NASDAQ: AVXL) surges to highs following this morning's testing deal with Biogen (NASDAQ: BIIB). Shares are up 46.8% on volume that is 37x normal.
... MoreBiogen (BIIB) to Test Anavex Life Sciences (AVXL) Lead Drug Candidate ANAVEX 2-73
September 28, 2016 7:02 AM EDTAnavex Life Sciences Corp. (Nasdaq: AVXL) signed a material transfer agreement with Biogen (NASDAQ: BIIB) under which Biogen will test Anavexs lead drug candidate, ANAVEX 2-73 in an oligodendrocyte precursor cell (OPC) differentiation assay. A... More
